India, June 22 -- InSilico Medicine Cayman TopCo (3696.HK) on Monday announced partnership with SK Biopharmaceuticals Co., Ltd. (326030.KS) to discover artificial intelligence-enabled drug candidates targeting neuroimmune disorders of the central nervous system, in a deal worth more than $2.5 billion.
Under the agreement, Insilico will use its proprietary Pharma.AI platform to discover and optimize drug candidates for neuroinflammatory, neurodegenerative and rare neurological diseases, while SK Biopharmaceuticals will lead late-stage development and commercialization.
Insilico said it will be eligible to receive up to $18 million in upfront and near-term milestone payments. The agreement also includes development, regulatory and commercia...